IPMK

Across TCGA pan-cancer cohorts, IPMK mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IPMK data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IPMK mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated IPMK expression acts as an unfavorable survival marker.

HNSC, LUAD, and LSCC are the cancer types where IPMK mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.804	1.000	.029	4	view →
LUAD	DFS	Median	III,IV	0.422	1.000	.038	3	view →
LSCC	DFS	Tertile	II,III,IV	0.201	1.000	.038	2	view →
PDAC	OS	Quartile	All	0.441	0.741	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

IPMK–HNSC (DFS)

Open the HNSC breakdown →